A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Active, not recruitingPhase 3NCT07035093
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
Brief summary (from the registry)
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
Study details
- Official title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
- Conditions
- Obesity
- Overweight
- Chronic Low Back Pain (CLBP)
- Interventions
- Drug: Retatrutide
- Drug: Placebo
- Sponsor
- Eli Lilly and Company
- Start date
- 2025-05-29
- Primary completion
- 2027-09
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Argentina, Canada, Poland, United States
- Total sites listed
- 40
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Have a history of axial-predominant low back pain * Have pain that is restricted to the low back or with a referral pattern limited to the proximal legs * Have a body mass index (BMI) ≥27 kilograms per square meter (kg/m2) at screening * Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * Have a non-axial origin low back pain * Have had botulinum or steroid injections to the spine within 1 year of screening * Have had trigger point injection to the spine within 6 months of screening * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days prior to screening * Have been taking drugs to promote body weight reduction, including over-the-counter medications, within 90 days prior to screening * Have a prior or planned surgical treatment for obesity * Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes
Canadian sites (5)
| Facility | City | Province |
|---|---|---|
| Aggarwal and Associates Limited | Brampton | |
| Winterberry Research Inc. | Hamilton | |
| Bluewater Clinical Research Group Inc. | Sarnia | |
| Care Access - Cape Breton | Sydney | |
| Dr. Anil K. Gupta Medicine Professional Corporation | Toronto |
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07035093